Ubretid is a potent inhibitor of plasma cholinesterase. Ubretid therefore delays the hydrolysis of suxamethonium and prolongs its action, similar to the effects shown by other anticholinesterase drugs, such as pyridostigmine and donepezil. Ubretid has the potential for the research of urinary retention prolongs the effect of suxamethonium. Ubretid is commonly prescribed for the research of myasthenia gravis and for difficulty in emptying the bladder[1].
[1]. Isono S, et al. Ubretid (distigmine bromide) taken to treat urinary retention prolongs the effect of suxamethonium. J Anesth. 2008;22(3):337.